Optiscan Imaging Teams With Mayo Clinic To Develop Robotic Imaging Platform

Optiscan Imaging Ltd (ASX: OIL) has entered into a collaboration with Mayo Clinic to develop an imaging system for use in robotic surgery.

The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic development with Mayo Clinic’s know-how in robotic surgery.

The agreement, which covers a 24-month co-development plan, will bring together experts from both companies.

They will develop a robot-compatible endomicroscopic imaging system initially focusing on robotic-assisted breast cancer surgery.

“Shared history of innovation”

The US robotic surgery service market was valued at US$1.8 billion in 2022 and is estimated to grow 17.3% annually to reach US$6.4 billion in 2030.

Optiscan CEO and Managing Director Dr Camile Farah said: “We’re excited to collaborate with Mayo Clinic to accelerate the development and clinical testing of our robotic imaging platform with the aim of fast-tracking the adoption of real-time digital pathology and image guided precision robotic surgery.

“This collaboration is built on a shared history of innovation and a laser focus on delivering the highest quality patient outcomes for better health care delivery.”

Focus on US market

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world.

The hospital undertakes more than 141,000 surgical cases and performs more than 4,000 robotic surgery cases a year.

Dr Farah added: “The collaboration is part of Optiscan’s wider strategic focus on the US market, and its plan to embed its platform technology as a key component of intraoperative oncological surgery workflows in a variety of settings and clinical applications to provide surgeons with realtime microscopic information of cancer clearance for the potential to reduce missed cancers and minimise repeat surgeries due to residual disease.”

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest